Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study
Clinical and Translational Radiation Oncology · 2027-01 · 62 · 101310
DOI: 10.1016/j.ctro.2026.101310 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Translational Radiation Oncology, 2027-01. Verfasst von Zhengting Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospi…. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kunming Medical University, Cancer Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND AND PURPOSE: Cranial radiotherapy (RT) and pyrotinib both demonstrate efficacy in HER2-positive breast cancer brain metastases (BCBM); however, the optimal sequencing of these modalities remains to be established. We evaluated survival across treatment sequences within a real-world cohort. MATERIALS AND METHODS: This retrospective, two-centre study included 101 patients with HER2-positive BCBM treated with cranial RT plus pyrotinib (June 2018-July 2025). Based on treatment sequence, patients were categorized into: concurrent RT and pyrotinib (Group A, n = 41); RT after intracranial progression on pyrotinib (Group B, n = 38); and pyrotinib upon progression following RT (Group C, n = 22). The primary endpoint was CNS-PFS. Survival outcomes were assessed via Kaplan-Meier estimation and Cox proportional hazards models. RESULTS: At a median follow-up of 43.3 months, 63 patients (62.4%) had died and 70 (69.3%) experienced CNS-PFS events. Median CNS-PFS was 14.8 months (95% CI 10.68-19.92) overall, and 14.3, 15.0, and 21.4 months in groups A, B, and C, respectively (P = 0.252); median OS was 36.0 months (95% CI 28.0-39.7) overall, and 33.0, 35.4, and 42.0 months in groups A, B, and C, respectively (P = 0.281). Focal cranial RT was independently associated with longer OS (HR 0.56, 95% CI 0.34-0.94; P = 0.028). Any-grade adverse events occurred in 100 of 101 patients (99.0%); grade ≥ 3 events occurred in 2.4%, 7.9%, and 4.5% of groups A, B, and C, respectively (all P > 0.05), and radiation necrosis occurred in 7 patients (6.9%). An exploratory threshold of RT initiated >3.9 months before pyrotinib (OS 49.9 vs 29.8 months; HR 0.31, 95% CI 0.11-0.91; P = 0.025) did not withstand internal validation. CONCLUSIONS: Treatment sequence did not significantly affect OS or CNS-PFS. Focal cranial RT was independently associated with longer survival, and toxicity was manageable. The proposed timing threshold is hypothesis-generating and warrants prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming 650118, China.
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Yunnan Key Laboratory of Breast Cancer Precision Medicine, The Department of Breast Surgery, Breast Cancer Center of the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University…
Förderung
- Kunming Medical University
- Cancer Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Chen, Z., Jing, H., Huang, S., Wang, M., Mao, D., Li, L., Lu, S., Zhou, X., Bi, D., Zhang, Y., Chen, X., Ma, Y., Xia, Y., Yi, J., & Hou, Y. (2027). Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study. Clinical and Translational Radiation Oncology, 62, 101310. https://doi.org/10.1016/j.ctro.2026.101310
Vancouver
Chen Z, Jing H, Huang S, Wang M, Mao D, Li L, et al. Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study. Clinical and Translational Radiation Oncology. 2027;62:101310. doi:10.1016/j.ctro.2026.101310
BibTeX
@article{Chen2027,
author = {Chen, Zhengting and Jing, Hao and Huang, Sheng and Wang, Miao and Mao, Dan and Li, Lan and Lu, Shuang and Zhou, Xinyan and Bi, Dongyu and Zhang, Ye and Chen, Xuesong and Ma, Yuchao and Xia, Yaoxiong and Yi, Junlin and Hou, Yu},
title = {Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study},
journal = {Clinical and Translational Radiation Oncology},
year = {2027},
volume = {62},
pages = {101310},
doi = {10.1016/j.ctro.2026.101310}
}
EUVIMED